Toll-like receptor (TLR) 2 specific and antagonistic monoclonal antibody
TLR2 represents an “earliest possible” target for prevention and therapeutic
intervention in the pathogenesis of harmful immune reactions whose blockage abrogates entry of the initial inflammatory signal into first-line defense host cells.
Further Information: PDF
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Phone: +49 (0)89/1205-6000
Contact
Dr. Wolfgang Knappe
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Self-Destructing Cancer Cells: Cutting-Edge RNA Breakthrough
Jülich scientists use novel RNA technology to selectively switch off tumours in the brain. An Adaptable Platform Technology That Destroys Glioblastoma Cancer Cells Using a special RNA molecule, a team…
Endurance Training: Transforming Lives of Heart Failure Patients
Can strength and endurance training be beneficial for patients with a certain form of heart failure? A research team from Greifswald investigated this question together with seven other research centers…
A Wake-Up Call for Mediterranean Shark Protection Against Extinction
Overfishing, illegal fishing and increasing marketing of shark meat pose significant threats to the more than 80 species of sharks and rays that inhabit the Mediterranean Sea, according to a…